Abstract Number: 634 • 2016 ACR/ARHP Annual Meeting
Use of Biosimilars in Clinical Practice: A Swedish National Register-Based Assessment
Background/Purpose: In March 2015 the first infliximab biosimilars CT-P13 (Remsima™; Inflectra™), entered the Swedish market. The aim of this study was to evaluate the uptake…Abstract Number: 635 • 2016 ACR/ARHP Annual Meeting
Factors Associated to Lack of Adherence to Subcutaneous Biological Medications in Patients with Rheumatoid Arthritis from Spain. Arco Study
Background/Purpose: To investigate the variables associated to lack of adherence to subcutaneous (SC) biological drug in patients with rheumatoid arthritis (RA) after 1 year of…Abstract Number: 636 • 2016 ACR/ARHP Annual Meeting
Prospective, Intervention, Multicenter Study of Utility of Biologic Drug Monitoring with Respect to the Efficacy and Cost of Adalimumab Tapering in Patients with Rheumatic Diseases (34-week descriptive data)
Background/Purpose: Adalimumab (ADL) dose tapering based on clinical assessment is a usual practice especially in patients who have achieved clinical remission. The primary aim of…Abstract Number: 637 • 2016 ACR/ARHP Annual Meeting
Biologic Initiation Patterns Among Rheumatoid Arthritis Patients in Moderate or High Disease Activity While Using Conventional Disease Modifying Anti-Rheumatic Drugs
Background/Purpose: The purpose of this study was to describe biologic initiation patterns over a 1-year follow-up period in rheumatoid arthritis (RA) patients with moderate…Abstract Number: 638 • 2016 ACR/ARHP Annual Meeting
A Randomized, Open-Label, Single-Dose, Parallel-Group Trial to Determine the Pharmacokinetics, Safety and Immunogenicity of GP2017, a Proposed Adalimumab Biosimilar, Following a Single Subcutaneous Injection By an Autoinjector or Prefilled Syringe in Healthy Male Subjects
Background/Purpose: The purpose of this study was to describe the pharmacokinetics (PK), safety and immunogenicity of GP2017, a proposed adalimumab biosimilar, administered as a single…Abstract Number: 639 • 2016 ACR/ARHP Annual Meeting
Switching to Biosimilars in Rheumatology: Evidence-Based Practice
Background/Purpose: Biosimilars of originator biologic therapeutics are entering the market, and health care professionals and patients need a clear understanding of these new treatments. The…Abstract Number: 640 • 2016 ACR/ARHP Annual Meeting
Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate
Background/Purpose: Obese rheumatoid arthritis (RA) patients (pts) may have higher levels of inflammatory mediators, greater joint swelling and tenderness, and suboptimal response to therapy. We…Abstract Number: 641 • 2016 ACR/ARHP Annual Meeting
Reduction of Concomitant Oral Methotrexate or Corticosteroids in Combination Treatment with Adalimumab Does Not Affect Effectiveness in Patients with Rheumatoid Arthritis
Background/Purpose: In rheumatoid arthritis (RA) patients (pts) receiving corticosteroids (CS) or methotrexate (MTX) with an anti-TNF, such as adalimumab (ADA), the concomitant CS or MTX…Abstract Number: 642 • 2016 ACR/ARHP Annual Meeting
Quality of Life Outcomes Following Therapy with Chs-0214 and Etanercept (Enbrel): Randomized, Double-Blind Study in Subjects with Rheumatoid Arthritis
Background/Purpose: CHS-0214 is in development as a proposed biosimilar of etanercept. This Phase III confirmatory, safety and efficacy study randomized and dosed 644 subjects with…Abstract Number: 643 • 2016 ACR/ARHP Annual Meeting
Exposure-Response Analyses of Efficacy of ABT-122, a Dual-Variable Domain Immunoglobulin (DVD-Ig™) Targeting TNF-α and IL-17A, Compared with Adalimumab in Subjects with Rheumatoid Arthritis and Background MTX
Background/Purpose: ABT-122 is a novel dual-variable domain immunoglobulin (DVD-IgTM), which specifically neutralizes both TNF alpha (TNFα) and interleukin-17A (IL-17). Both cytokines are expressed at increased…Abstract Number: 644 • 2016 ACR/ARHP Annual Meeting
Seroprevalence and Its Impact on Radiographic Damage in Korean Rheumatoid Arthritis Patients Starting Biologics
Background/Purpose: High titers of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACCP) are poor prognostic factors for rheumatoid arthritis (RA) patients. Only few studies…Abstract Number: 645 • 2016 ACR/ARHP Annual Meeting
Prospective Observational Real-Life Study (STRATEGE) Shows the Efficacy of Treat-to-Target Strategy and Methotrexate Monotherapy Optimization in Patients with Established Rheumatoid Arthritis
Background/Purpose: Current guidelines consider MTX as initial gold standard treatment for patients (pts) with RA. They also propose various strategies for MTX inadequate responders, among…Abstract Number: 646 • 2016 ACR/ARHP Annual Meeting
Population Pharmacokinetics of ABT-122, an Immunoglobulin Targeting Both TNF-α and IL-17A: Analyses Across Phase 1 Studies in Healthy Volunteers and Phase 2 Studies in Subjects with Rheumatoid or Psoriatic Arthritis
Background/Purpose: ABT-122 is a novel dual-variable domain immunoglobulin (DVD-IgTM), which specifically neutralizes both TNF alpha (TNFα) and interleukin-17A (IL-17). Drugs individually neutralizing TNFα or IL-17…Abstract Number: 647 • 2016 ACR/ARHP Annual Meeting
Genomic and Epigenetic Bioinformatics Demonstrate Dual TNF-α and IL17A Target Engagement By ABT-122, and Suggest Mainly TNF-α–Mediated Relative Target Contribution to Drug Response in MTX-IR Rheumatoid Arthritis Patients
Background/Purpose: ABT-122 is a dual variable domain (DVD-Ig) biologic which inhibits TNF-α and IL17A. In a 12-wk phase 2 study (NCT02141997) in MTX-IR patients (pts)…Abstract Number: 648 • 2016 ACR/ARHP Annual Meeting
ABT-122, an Anti-TNF/Anti-IL-17 Dual Variable Domain Antibody, Alters T Cell Responses in Human Subjects
Background/Purpose: ABT-122 is a dual variable domain antibody which neutralizes both TNF and IL-17 and is in Phase II trials for rheumatoid arthritis (RA) and…
ACR Meeting Abstracts